Rectal Cancer - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 106 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Rectal Cancer - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Rectal Cancer - Pipeline Review, H1 2015', provides an overview of the Rectal Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rectal Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rectal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Rectal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Rectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rectal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rectal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Rectal Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Rectal Cancer - Overview 8
Pipeline Products for Rectal Cancer - Comparative Analysis 9
Rectal Cancer - Therapeutics under Development by Companies 10
Rectal Cancer - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Rectal Cancer - Products under Development by Companies 14
Rectal Cancer - Companies Involved in Therapeutics Development 15
AbbVie Inc. 15
Apogenix GmbH 16
Cerulean Pharma, Inc. 17
GlaxoSmithKline plc 18
Hanwha Chemical Corporation 19
Incuron, LLC 20
Karyopharm Therapeutics, Inc. 21
Nanobiotix 22
Peregrine Pharmaceuticals, Inc. 23
Regeneron Pharmaceuticals, Inc. 24
Synta Pharmaceuticals Corp. 25
Rectal Cancer - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
APG-350 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
bavituximab - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CRLX-101 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ganetespib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
GSK-2256098 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
HD-204 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
mepacrine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
NBTX-IV - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
NBTXR-3 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
selinexor - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
veliparib - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ziv-aflibercept (recombinant) - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Rectal Cancer - Recent Pipeline Updates 67
Rectal Cancer - Dormant Projects 102
Rectal Cancer - Product Development Milestones 103
Featured News & Press Releases 103
Apr 23, 2014: Abbvie To Present Data On Veliparib At The 2014 American Society Of Clinical Oncology Annual Meeting 103
Nov 10, 2011: Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells To Chemoradiotherapy 103
Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 106
Disclaimer 106

List of Tables
Number of Products under Development for Rectal Cancer, H1 2015 8
Number of Products under Development for Rectal Cancer - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Rectal Cancer - Pipeline by AbbVie Inc., H1 2015 15
Rectal Cancer - Pipeline by Apogenix GmbH, H1 2015 16
Rectal Cancer - Pipeline by Cerulean Pharma, Inc., H1 2015 17
Rectal Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 18
Rectal Cancer - Pipeline by Hanwha Chemical Corporation, H1 2015 19
Rectal Cancer - Pipeline by Incuron, LLC, H1 2015 20
Rectal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 21
Rectal Cancer - Pipeline by Nanobiotix, H1 2015 22
Rectal Cancer - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015 23
Rectal Cancer - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 24
Rectal Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015 25
Assessment by Monotherapy Products, H1 2015 26
Number of Products by Stage and Target, H1 2015 28
Number of Products by Stage and Mechanism of Action, H1 2015 30
Number of Products by Stage and Route of Administration, H1 2015 32
Number of Products by Stage and Molecule Type, H1 2015 34
Rectal Cancer Therapeutics - Recent Pipeline Updates, H1 2015 67
Rectal Cancer - Dormant Projects, H1 2015 102